Drug Discovery World
MARCH 4, 2024
Clinical Microbiomics has acquired DNASense, a Danish microbiome clinical research organisation (CRO) specialised in long-read DNA and RNA sequencing technologies and bioinformatics. The acquisition adds long-read DNA and RNA sequencing technologies to Clinical Microbiomics’ multi-omics technologies for the microbiome field.
Scienmag
APRIL 20, 2021
Real-world disease and parasite monitoring is often hampered by the inability of traditional approaches to easily sample broad geographical areas and large numbers of individuals. This can result in patchy data that fall short of what researchers need to anticipate and address outbreaks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
OCTOBER 7, 2020
Computational algorithms enable identification and optimization of RNA-based tools for myriad applications DNA and RNA have been compared to “instruction manuals” containing the information needed for living “machines” to operate.
Scienmag
MAY 27, 2021
Capturing how RNA polymerase enzymes kick off transcription On scales too small for our eyes to see, the business of life happens through the making of proteins, which impart to our cells both structure and function.
XTalks
DECEMBER 13, 2023
Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. In the third quarter of 2023, the company’s revenue surged to $63.7
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). Optimal methods for bioinformatic analysis are still needed. percent show less reliability).
Drug Discovery World
JULY 11, 2023
Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.
Expert insights. Personalized for you.
52 
Let's personalize your content